Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 65

1.

Cannabinoid modulation of neuroinflammatory disorders.

Saito VM, Rezende RM, Teixeira AL.

Curr Neuropharmacol. 2012 Jun;10(2):159-66. doi: 10.2174/157015912800604515.

2.

Therapeutic potential of cannabinoids in CNS disease.

Croxford JL.

CNS Drugs. 2003;17(3):179-202. Review.

PMID:
12617697
3.

Cannabis and cannabinoids: pharmacology and rationale for clinical use.

Pertwee RG.

Forsch Komplementarmed. 1999 Oct;6 Suppl 3:12-5. Review.

PMID:
10575283
4.

Phytocannabinoids as novel therapeutic agents in CNS disorders.

Hill AJ, Williams CM, Whalley BJ, Stephens GJ.

Pharmacol Ther. 2012 Jan;133(1):79-97. doi: 10.1016/j.pharmthera.2011.09.002. Review.

PMID:
21924288
5.

The role of cannabinoid system on immune modulation: therapeutic implications on CNS inflammation.

Correa F, Mestre L, Molina-Holgado E, Arévalo-Martín A, Docagne F, Romero E, Molina-Holgado F, Borrell J, Guaza C.

Mini Rev Med Chem. 2005 Jul;5(7):671-5. Review.

PMID:
16026313
6.

CB receptor ligands from plants.

Woelkart K, Salo-Ahen OM, Bauer R.

Curr Top Med Chem. 2008;8(3):173-86. Review.

PMID:
18289087
7.

[The role of endocannabinoid system in physiological and pathological processes in the eye].

Nadolska K, Goś R.

Klin Oczna. 2008;110(10-12):392-6. Review. Polish.

PMID:
19195174
8.

[Cannabinoid system and neuroinflammation:therapeutic perspectives in multiple sclerosis].

Mestre L, Correa F, Docagne F, Clemente D, Ortega-Gutiérrez S, Arévalo-Martín A, Molina-Holgado E, Borrell J, Guaza C.

Rev Neurol. 2006 Nov 1-15;43(9):541-8. Review. Spanish.

9.

Pharmacology and toxicology of Cannabis derivatives and endocannabinoid agonists.

Gerra G, Zaimovic A, Gerra ML, Ciccocioppo R, Cippitelli A, Serpelloni G, Somaini L.

Recent Pat CNS Drug Discov. 2010 Jan;5(1):46-52. Review.

PMID:
19832688
10.

Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb.

Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R.

Trends Pharmacol Sci. 2009 Oct;30(10):515-27. doi: 10.1016/j.tips.2009.07.006. Review. Erratum in: Trends Pharmacol Sci. 2009 Dec;30(12):609.

PMID:
19729208
11.

Fungal biotransformation of cannabinoids: potential for new effective drugs.

Saxena S.

Curr Opin Drug Discov Devel. 2009 Mar;12(2):305-12. Review. Erratum in: Curr Opin Drug Discov Devel. 2009 Jul;12(4):562.

PMID:
19333876
12.

Cannabinoid modulation of peripheral autonomic and sensory neurotransmission.

Ralevic V.

Eur J Pharmacol. 2003 Jul 4;472(1-2):1-21. Review.

PMID:
12860468
13.
14.

The future of cannabinoids as analgesic agents: a pharmacologic, pharmacokinetic, and pharmacodynamic overview.

McCarberg BH, Barkin RL.

Am J Ther. 2007 Sep-Oct;14(5):475-83. Review.

PMID:
17890938
15.

Pharmacology of cannabinoids.

Grotenhermen F.

Neuro Endocrinol Lett. 2004 Feb-Apr;25(1-2):14-23. Review.

PMID:
15159677
16.

Cannabinoids and neurodegenerative diseases.

Romero J, Orgado JM.

CNS Neurol Disord Drug Targets. 2009 Dec;8(6):440-50. Review.

PMID:
19839933
17.

The neurobiology and evolution of cannabinoid signalling.

Elphick MR, Egertová M.

Philos Trans R Soc Lond B Biol Sci. 2001 Mar 29;356(1407):381-408. Review.

18.

[Therapeutic applications and biomedical effects of cannabinoids; pharmacological starting points].

Killestein J, Nelemans SA.

Ned Tijdschr Geneeskd. 1997 Aug 30;141(35):1689-93. Review. Dutch.

PMID:
9543785
19.

On the pharmacological properties of Delta9-tetrahydrocannabinol (THC).

Costa B.

Chem Biodivers. 2007 Aug;4(8):1664-77. Review.

PMID:
17712813
20.

Cannabinoids and the immune system: potential for the treatment of inflammatory diseases?

Croxford JL, Yamamura T.

J Neuroimmunol. 2005 Sep;166(1-2):3-18. Review.

PMID:
16023222
Items per page

Supplemental Content

Support Center